高验前概率肺栓塞患者的抢先抗凝:指南是否被遵循?
该研究回顾了两家急诊科连续3500例接受CTPA的患者,用修订版日内瓦评分(RGS)划分肺栓塞验前概率。在117例高验前概率(RGS 11-18)患者中,仅2例(1.7%)在CTPA完成前接受抢先抗凝;从急诊注册到CTPA完成的时间不因验前概率不同而异。结论是医生很少对高验前概率肺栓塞患者实施抢先抗凝,也未加快CTPA检查。
要点
- 高验前概率肺栓塞患者中抢先抗凝实施率极低(1.7%)。
- 高验前概率患者未获得更快的CTPA检查。
- 多数高验前概率患者已有抗凝指征却未抢先抗凝。
核心结论
- 医生很少对高验前概率肺栓塞患者使用抢先抗凝。
- 临床医生不会为高验前概率肺栓塞患者加快CTPA检查。
研究设计与样本
- 回顾性研究,纳入两家急诊科连续3500例接受CTPA的患者。
- 排除3例CTPA先于急诊注册者,分析3497例。
- 用修订版日内瓦评分(RGS)将验前概率分为低(0-3)、中(4-10)、高(11-18)。
主要发现
- 167例(4.8%)患者为高验前概率肺栓塞。
- 排除高出血风险29例和CTPA前已治疗DVT 21例后,117例高验前概率患者中仅2例(1.7%)接受抢先抗凝。
- 剩余115例高验前概率患者中37例(32%)有预先存在的抗凝指征但未接受抢先抗凝。
- 从急诊注册到CTPA完成的时间不因验前概率不同而异。
关键数值与推荐
- 高验前概率定义为修订版日内瓦评分(RGS)11-18。
- 抢先抗凝定义为CTPA完成前给予治疗性抗凝。
临床怎么用
- 对高验前概率肺栓塞患者,应评估是否需在等待CTPA结果期间抢先抗凝。
- 高验前概率患者中多数有抗凝指征但未实施,提示需改进流程。
- 高验前概率患者未获得更快的CTPA检查,提示需优化检查优先级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines suggest anticoagulation of patients with high pretest probability of pulmonary embolism (PE) while awaiting diagnostic test results (preemptive anticoagulation). Data relevant to the practice of preemptive anticoagulation are not available. METHODS: We reviewed 3,500 consecutive patients who underwent CT pulmonary angiography (CTPA) at two EDs. We classified the pretest probability for PE using the revised Geneva Score (RGS) as low (RGS 0-3), intermediate (RGS 4-10), or high (RGS 11-18). We classified patients with a high pretest probability of PE as receiving preemptive anticoagulation if therapeutic anticoagulation was given before CTPA completion. Patients with a high bleeding risk and those receiving treatment for DVT before CTPA were excluded from the preemptive anticoagulation analysis. We compared the time elapsed between ED registration and CTPA completion for patients with a low, intermediate, and high pretest probability for PE. RESULTS: We excluded three of 3,500 patients because CTPA preceded ED registration. Of the remaining 3,497 patients, 167 (4.8%) had a high pretest probability for PE. After excluding 29 patients for high bleeding risk and 21 patients who were treated for DVT prior to CTPA, only two of 117 patients (1.7%) with a high pretest probability for PE received preemptive anticoagulation. Furthermore, 37 of the remaining 115 patients (32%) with a high pretest probability for PE had a preexisting indication for anticoagulation but did not receive preemptive anticoagulation. The time from ED registration to CTPA completion did not differ based on the pretest probability of PE. CONCLUSIONS: Physicians rarely use preemptive anticoagulation in patients with a high pretest probability for PE. Clinicians do not expedite CTPA examinations for patients with a high pretest probability for PE.
引用
- Willoughby L, Adams DM, Evans RS, et al. Preemptive Anticoagulation in Patients With a High Pretest Probability of Pulmonary Embolism: Are Guidelines Followed? Chest. 2017. PMID: 29154971. doi:10.1016/j.chest.2017.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。